Recent Quotes (30 days)

You have no recent quotes
chg | %

Miraculins Inc  

(Public, CVE:MOM)   Watch this stock  
Find more results for MOM
-0.0050 (-20.00%)
Delayed:   10:07AM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.02 - 0.03
52 week 0.01 - 0.29
Open 0.03
Vol / Avg. 181,500.00/445,039.00
Mkt cap 1.01M
P/E     -
Div/yield     -
EPS -0.12
Shares 50.52M
Beta 0.12
Inst. own     -

Key stats and ratios

Q2 (May '15) 2015
Net profit margin -46247.02% -
Operating margin -38852.24% -
EBITD margin - -
Return on average assets -173.10% -
Return on average equity - -
CDP Score - -


6-1250 Waverley St
+1-204-4531408 (Phone)
+1-204-4531546 (Fax)

Website links


Miraculins Inc. (Miraculins) is a Canada-based medical device company. The Company is engaged in developing non-invasive diagnostic tests and risk assessment technologies. The Company's lead technology program is in the early commercialization phase in the area of diabetes risk assessment. The diabetes program is focused on the Scout DS Non Invasive Diabetes Screening Test, a non-invasive diabetes screening system designed to provide a method for diabetes screening based on diabetes related biomarkers present in the skin. Miraculins' other technology related to cardiovascular disease is focused on the PreVu Non Invasive Skin Cholesterol Point of Care (POC) Test, a non-invasive tool to assist with the risk assessment of coronary artery disease (CAD). The PreVu technology also has a lab processed format called the PreVu Non Invasive Skin Cholesterol Lab Processed (LP) Test. Miraculins' preeclampsia technology is based on a range of protein biomarkers.

Officers and directors

Harry Bloomfield Independent Chairman of the Board
Christopher Moreau President, Chief Executive Officer, Director
James F. Kinley Chief Financial Officer
Age: 37
William Dwight Roberts Independent Director
Michael Stasiuk Independent Director